Adaptimmune to Participate in Two Upcoming Investor Conferences

PHILADELPHIA, and OXFORD, United Kingdom, Sept. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its participation in the following two September conferences:

  • James Noble, Adaptimmune’s chief executive officer, will present at the 2016 Morgan Stanley Global Healthcare Conference on Tuesday September 13, 2016 at 8:00AM EDT (1:00 PM BST). The conference is being held at the Grand Hyatt New York;
  • Adrian Rawcliffe, Adaptimmune’s chief financial officer, will present at the Leerink Partners Roundtable Series: Rare Disease and Immuno-Oncology on Thursday September 29, 2016 at 8:30 AM EDT (1:30 PM BST). The conference is being held at the Lotte New York Palace hotel.

Adaptimmune’s presentations at these conferences will be webcast live for investors through the investor section of www.adaptimmune.com and available for a period of 30 days following the conferences.

About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell platform. Established in 2008, the company aims to utilize the body’s own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is a SPEAR T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO SPEAR T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, Adaptimmune has a number of proprietary programs. These include SPEAR T-cell therapies targeting the MAGE-A10 and AFP cancer antigens, which both have open INDs, and a further SPEAR T-cell therapy targeting the MAGE-A4 cancer antigen that is in pre-clinical phase with IND acceptance targeted for 2017. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 250 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com

Adaptimmune Contacts Will Roberts Vice President, Investor Relations T: (215) 825-9306 E: will.roberts@adaptimmune.com Margaret Henry Head of PR T: +44 (0)1235 430036 Mobile: +44 (0)7710 304249 E: margaret.henry@adaptimmune.com

Source:Adaptimmune Therapeutics plc